Targovax ASA – Additional information prior to the Extraordinary General Meeting

Oslo, Norway, 1 March 2023: Reference is made to Targovax ASA's ("Targovax" or the "Company") stock exchange announcement on 16 February 2023 where the Company called for an extraordinary general meeting (EGM) to be held at the Company’s offices at Lysaker on 9 March 2023 at 10:00 CET for the purpose of approving the investment agreement for up to NOK 300m in convertible bonds with Atlas Special Opportunities, LLC (“Atlas”).

Important and relevant parts of the Investment and Subscription Agreement with Atlas has been published on the Company’s website: https://www.circio.com/en/extraordinary-general-meeting-2023/ and is also attached to this notice.

A webcast presentation with a Q&A regarding the Atlas convertible bond facility was held 28 February 2023. A recording of the presentation and the presentation material is available on our web site on the following link: https://www.circio.com/en/presentations/.

Attachment: Atlas investment Agreement Public Terms


For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax’s focus is to activate the patient’s immune system to fight cancer, and to bring benefit to cancer patients with few available treatment alternatives. Targovax is developing its product candidates in different cancer indications, including melanoma, mesothelioma, multiple myeloma and pancreatic cancer.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system against the tumor. ONCOS-102 has demonstrated a favorable efficacy, immunological and safety profile in several indications, both as monotherapy and in combinations, and ONCOS-102 is progressing into a randomized phase 2 trial in melanoma patients resistant to PD-1 checkpoint inhibitor treatment.

Targovax has also established a cutting-edge circular RNA (circRNA) program with the intent to develop next generation RNA therapeutics for various applications, building on clinical experience and deep mechanistic insights from its first generation products.  In addition, Targovax has a KRAS immunotherapy program, with lead candidate TG01 due to enter clinical trials in an enhanced format in pancreatic cancer and multiple myeloma during early 2023. This provides Targovax with a rich pipeline of innovative future therapeutic candidates to follow ONCOS-102.